On October 2, 2026 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), reported that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
One presentation will focus on promising Phase 2 results for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The second presentation will feature encouraging Phase 1/2 data for imneskibart with and without nivolumab in doublet CPI-refractory cutaneous melanoma. The SITC (Free SITC Whitepaper) Annual Meeting is being held virtually and in Phoenix, Arizona, from November 4-8, 2026.
Details of the poster presentations are as follows:
Title: Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: Phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
Abstract: 605
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST
Title: Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study
Abstract: 611
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST
The posters will be presented in the Poster Hall (Exhibit Halls AB) at the Phoenix Convention Center. Electronic versions will also be available on the SITC (Free SITC Whitepaper) 2026 virtual meeting platform.
About Imneskibart
Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.
To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).
(Press release, Aulos Bioscience, OCT 2, 2026, View Source [SID1234671239])